51 results about "Envelope Gene" patented technology

Non-infectious, retrovirus-like particles comprise an assembly of an env gene product, a pol gene product and a gag gene product contain an antigenic marker which is non-retroviral or non-HIV retroviral. In one embodiment, the marker comprises an amino acid sequence containing an epitope inserted into the gag gene product at an antigenically-active insertion site. In another embodiment, the marker comprises an antigenic anchor sequence operatively connected to the env gene product replacing endogenous anchoring function. The corresponding nucleic acid molecules are described. The non-infectious, retrovirus-like particles have utility in in vivo administration including to humans and in diagnosis. The presence of the antigenic marker enables recognition that antiserum containing anti-retroviral antibodies has been generated by exposure to the non-infectious retrovirus-like particles by testing for antibodies specific to the antigenic marker.

Compositions, kits and methods for boosting, or for priming and boosting, high titer broadly neutralizing cross-clade antibody responses focused on single HIV-1 neutralizing epitopes are disclosed. gp120 DNA plasmids comprising HIV env genes are used to prime the antibody response. Primed subjects are immunized with recombinant fusion proteins that comprise a “carrier” protein fusion partner, preferably a truncated form of the MuLV gp70 Env protein, and a desired HIV neutralizing epitopes. Preferred epitopes are epitopes of V3 from one or more HIV clades. Immune sera from such immunized subjects neutralized primary isolates from virus strains heterologous to those from which the immunogens were constructed. Neutralizing activity was primarily due to V3-specific antibodies and cross-clade neutralizing Abs were present. This approach results in more potent and broader neutralizing antibody levels, a result of “immunofocusing” the humoral immune response on neutralizing epitopes such as V3.

The invention concerns a purified recombinant glycoprotein having the following properties: a) an adherence capacity to CD4; b) an affinity with a anti-gp120 antibody capable of neutralizing in vitro HIV cell infection; c) an affinity with an anti-gp41 antibody; d) a timeric form free from inter-chain disulphide bonds. The invention also concerns a vaccine comprising said purified glycoprotein and an adjuvant. The invention further concerns a method for obtaining said glycoprotein, which consists in expressing, by means of genetic recombining techniques, a glycoprotein corresponding to the properties a), b) and c) mentioned above; purifying it, and subjecting it to steps involving at least a reducing agent, an ionic detergent and/or a neutral detergent in conditions leading to a glycoprotein having said properties.

PCT No. PCT/US96/07370 Sec. 371 Date Nov. 28, 1997 Sec. 102(e) Date Nov. 28, 1997 PCT Filed May 22, 1996 PCT Pub. No. WO96/37625 PCT Pub. Date Nov. 28, 1996Recombinant avian sarcoma leukosis virus (ASLV)-derived retrovirus vectors having an expanded host range are described. The host range is expanded by the replacement of the ASLV envelope gene by an envelope gene from a virus capable of infecting both mammalian and avian cells. The resulting recombinant ASLV-derived retroviral vectors can replicate efficiently in avian cells, infect both avian and mammalian cells in high titer, and are replication-defective in mammalian cells. Thus, they are quite safe and advantageous for use in gene therapy and vaccines.

Disclosed are a diagnosis method and a therapeutic method for cancer, both of which utilize HERV-H env gene and protein. Particularly, cancer can be diagnosed by detecting the expression of HERV-H env gene, and a reagent used for the detection of the expression can be used as a diagnosing agent. Cancer can be treated by inhibiting the function of HERV-H env gene, and a reagent used for the inhibition of the function can be used as an anti-cancer agent. Alternatively, cancer can be treated by administering a peptide having a specific sequence contained in HERV-H env protein or the like, and the peptide or the like can be used as a cancer vaccine.

The N-acetylglucosaminyltransferase III activity is enhanced in a cell carrying retrovirus-origin gag-pol gene and env gene. By constructing a retrovirus vector with the use of the above cell, a retrovirus vector having a modified sugar chain structure can be obtained. The retrovirus vector constructed by this method shows a high infection efficiency particularly in the presence of a functional substance.

The invention belongs to the cross technical field of molecular immunology and virology, and particularly relates to a monoclonal antibody of avian reticuloendotheliosis virus envelope protein. The monoclonal antibody is characterized in that 1200bp of genetic fragment in a relative conservation region of an avian reticuloendotheliosis virus (REV) envelope (env) gene is selected, and 400 amino acids expressed by the fragment comprise more than 90% of antigen sites of the REV, so that most of the antigen sites of the virus are retained and the interference caused by genovariation is excluded, prokaryotic expression product His-env fusion protein is obtained by utilizing the env gene containing the conservation genetic fragment, the Balb/C mouse is immunized by the fusion protein, and the monoclonal antibody of the REV ENV (envelope) protein is obtained through fusion of oncocyte SP2/0 and splenocyte of the immunized mouse, screening and cloning. The monoclonal antibody provides a technical support for diagnosis and prevention as well as scientific research of avian reticuloendotheliosis.

The invention relates to double bond small molecule disturbance ribonucleic acid to prevent and cure AIDS. The double bond small molecule disturbance ribonucleic acid is RNA double bond molecule, which is called siRNA double bond molecule that has 19 base pairings. Two protrude basic groups dT are on the ends of 5' of positive bond and negative bond. GC content is 40-55%. Target sequence is gag gene, pol gene, vif gene, vpr gene, env gene, and nef gene selected from HIV gene. The positive bond sequence of siRNA double bond molecule is selected from SEQ ID NO.1-116, and the negative bond is corresponding to positive sequence. The invention conquers the problem of validity decreasing or losing effectiveness of siRNA because of the mutation of HIV-I virus.

The present invention provides primers and a detection kit for avian leukosis J subgroup virus PCR detection. According to the present invention, PCR detection primers are designed by analyzing avian leukosis J subgroup virus env gene, wherein nucleotide sequences of the primers are represented by sequence lists SEQ ID No.1 and SEQ ID No.2; and the primers have good specificity, and the detection method has characteristics of rapidness, simpleness, high accuracy and good sensitivity so as to provide an excellent detection method for avian leukosis J subgroup virus identification. The present invention further provides a detection kit for the avian leukosis virus, wherein the detection kit comprises a primer pair represented by the sequence lists SEQ ID No.1-2.

The invention discloses an MIA primer, a probe and a kit for detecting COVID-19 and an application of the MIA primer and the probe. According to the invention, the MIA primer and the probe are respectively designed based on a nucleocapsid N gene, an envelope E gene and an ORF1ab region of the COVID-19 publicized by NCBI. According to the MIA method disclosed by the invention, the detection of ORF1ab, E and N target genes of COVID-19 is realized in 3-15 minutes for the first time, and the detection sensitivity reaches 100 copies/ml (sample template concentration). The MIA method has no non-specific cross reaction with pathogen nucleic acid samples such as type A influenza, type B influenza and respiratory syncytial virus.

The present invention relates to non-replicative recombinant retrovirus packaging cells able to grow in suspension in a serum-free medium. In particular, the present invention relates to a human embryonic 293SF-based cell line stably expressing gag and pol gene products from the murine Moloney leukemia virus (MLV) and the feline RD114 env gene. This particular combination allows the production of high titer of non-replicative retrovirus pseudotyped and prevents the recombination of plasmids. The recombinant retroviruses produced from these cells are safer and easier to produce for clinical use in gene therapy.

The invention discloses a recombined chicken Marek's disease virus vaccine strain for expressing Gag and Env genes of an avian leukosis virus subgroup J (ALV-J) and a construction method and application of the recombined chicken Marek's disease virus vaccine strain, and belongs to the technical field of medicine or veterinary medicine. By means of the recombination and clone technology, a gene segment CAG-ALVGE containing the ALV-J Gag and Env genes and a CAG promoter sequence is inserted in a US2 gene of the strain 814 of the chicken Marek's disease virus, a recombined cosmid with a CAG-ALVGE expression frame inserted in a US2 gene is constructed, and the recombined chicken Marek's disease virus vaccine strain for expressing the Gag and Env genes is obtained through salvation of the recombined cosmid. Research shows that the obtained vaccine strain has the same in-vitro replication ability as a parent virulent vaccine strain 814 and good hereditary stability, and can resist attacks of a very virulent MDV strain and a very virulent ALV-J strain at the same time. It can be seen that the obtained recombined MDV vaccine strain can be used for preparing medicine for preventing or treating avian leukosis and the chicken Marek's disease.

Nucleic acid constructs containing HIV-1 gag/pol and SIV gag or SIV genes which have been mutated to remove or reduce inhibitory/instability sequences are disclosed. Viral particles and host cells containing these constructs and/or viral particles are also disclosed. The exemplified constructs and viral particles of the invention may be useful in gene therapy for numerous disorders, including HIV infection, or as a vaccine for HIV-1 immunotherapy and immunoprophylaxis.

The present invention relates to non-replicative recombinant retrovirus packaging cells able to grow in suspension in a serum-free medium. In particular, the present invention relates to a human embryonic 293SF-based cell line stably expressing gag and pol gene products from the murine Moloney leukemia virus (MLV) and either the feline RD114 env gene, the gibbon ape leukemia virus (GLV) env gene, or the amphotropic 4070Aenv gene. This particular combination allows the production of high titer of non-replicative retrovirus pseudotyped and prevents the recombination of plasmids. The recombinant retroviruses produced from these cells are safer and easier to produce for clinical use in gene therapy.

The invention relates to construction and function test of a double-long-hairpin RNA (Ribonucleic Acid) expression element for inhibiting HIV-1 (Human Immunodeficiency Virus-1), belonging to the technical field of gene engineering. In accordance with the design principle of siRNA and the conservative analysis of the HIV-1 sequence, an HIV-1 capsid protein gag gene (532-552), an envelope protein env gene (1428-1448), a non-structural protein tat gene (131-151) and a vpu gene (143-161) are selected and designed into a corresponding siRNA sequence; through a two-step PCR (Polymerase Chain Reaction) method, a double-long-hairpin RNA expression element (the sequence list is shown as SEQ ID No.1) is finally constructed; and through microscopic fluorescent observation and flow cell analysis quantitative test, the inhibition effect of the double-long-hairpin RNA expression element on the eukaryotic expression of an HIV gene EGFP (Enhanced Green Fluorescent Protein) fusion protein is tested. Experiments prove that the dlh RNA expression element can effectively inhibit the expression of multiple HIV genes.

The invention relates to the technical field of biology, and particularly discloses a recombinant immunodeficiency plasmid and virus and application thereof. The immunodeficiency plasmid comprises LTR, gag gene, nucleotide sequence disclosed as SEQ ID No.1, vif gene, vpr gene, vpx gene, tat gene, rev gene, env gene and nef gene. The nucleotide sequence disclosed as SEQ ID NO.1 is introduced to the pathogenic SIVmac239 full-length plasmid frame to construct the immunodeficiency plasmid comprising a plurality of drug target spots, and packaging is performed in the 293T cell to generate immunodeficiency virus. The virus has the capacity for infecting target cells and the capacity of efficient replication, and is applicable to researching human immunodeficiency virus (HIV) in-vivo infection process, pathogeny characteristic, pathogenesis and immunoreaction and screening anti-HIV drugs and anti-HIV drug application strategies.

The invention provides a modified CRF01_AE env gene. According to the modified CRF01_AE env gene, the GC content is increased, and an internal inhibitory sequence (INS) with higher AU content is damaged, so that the gene is more suitable for being expressed in a eukaryotic cell. The gene can be expressed efficiently in the eukaryotic cell without depending on regulatory protein Rev and a response element of the regulatory protein Rev; compared with the gene before modification, the expression quantity is remarkably increased; the modified mod.AE env gene is selected as a vaccine gene; and if HIV-1 vaccines are restructured, the immunogenicity of the vaccines can be improved possibly.

The invention discloses a method for constructing a recombinant virus for expressing an ALV-K envelope protein, specifically comprising the following steps: designing a PCR amplification ALV-J infectious clone linear expression vector primer and a PCR amplification ALV-K-env gene primer sequence; carrying out PCR amplification on an ALV-K envelope protein gene fragment and the ALV-J infectious clone linear vector, constructing a recombinant infectious cloning plasmid, and transfecting the recombinant plasmid into DF-1 cells to rescue the recombinant virus for expression of the ALV-K envelope protein. By ALV-J infectious cloning, the recombinant virus for efficient replication and expression of the ALV-K envelope protein is constructed. The acquisition of the recombinant virus not only laysa foundation for studying functional receptors of the ALV-K envelope protein and its pathogenicity, but also provides a target virus for the clinical detection of neutralizing antibodies of the ALV-K.

Belonging to the field of molecular biological technologies, the invention relates to a lentiviral vector of pseudotyped lymphocytic choriomeningitis virus glycoprotein. The cell line provided in the invention contains a retrovirus gag gene, a pol gene, an env gene, a retroviral regulatory gene, a gp gene for encoding the glycoprotein LCMV virus GP1 and GP2. The invention first puts forward that a vector system can be manufactured under the conditions of high titer and high concentration. Vector particles can be purified without any infectious material loss. The cell line involved in the invention has a wide and cross-species host cell spectrum.

The invention belongs to the technical field of biomedicine, and particularly relates to an HTLV-1 Env mediated cell-cell fusion model as well as a preparation method and application. According to theinvention, an HTLV-1 Env gene segment is obtained, a corresponding gp145 fragment in an HIV-1 Env gene of a vector pSRHS-Tat-EnvHIV-1 is replaced with the HTLV-1 Env gene segment, transfecting is performed with effector cells COS-1, and the effector cells and TZM-bl cells integrated with LTR and firefly luciferase reporter genes connected in series at the downstream of the LTR in a genome are co-cultured; the HTLV-1 Env mediated cell-cell fusion ability is indirectly detected by detecting the activity of firefly luciferase. The fusion system is verified by utilizing the inhibitory polypeptideP-400, which shows that the system is very suitable for screening and verifying HTLV-1 virus entry inhibitors and evaluating indexes such as effective concentration and toxicity of the entry inhibitors.